Bulk Pharmaceutical API Sources for tolvaptan

Bulk Pharmaceutical API Sources for tolvaptan

Vendor	Vendor Homepage	Vendor Sku	API Url
Amadis Chemical		A809063
AKos Consulting & Solutions		AKOS015994735
MedChemexpress MCE		HY-17000
AbaChemScene		CS-0572
Molport		MolPort-008-155-996
AstaTech, Inc.		40033

Bulk API Sources for Tolvaptan

Last updated: February 20, 2026

Identifying reliable bulk active pharmaceutical ingredient (API) sources for Tolvaptan involves examining key manufacturers, geographic distribution, and supply chain reliability. Tolvaptan, a vasopressin V2 receptor antagonist used for hyponatremia associated with syndromes such as SIADH and autosomal dominant polycystic kidney disease (ADPKD), is produced by a limited number of companies.

Major API Manufacturers and Suppliers

Company	Location	API Production Status	Certification	Approximate Capacity	Notes
Otsuka Pharmaceutical Co.	Japan	Commercial manufacturing	GMP-certified	Estimated 10-20 metric tons annually	Original developer and primary supplier; APIs often used in proprietary formulations
Kissei Pharmaceutical Co.	Japan	Licensed manufacturing	GMP-compliant	Data not publicly available	Licenses Otsuka rights under specific arrangements
Dr. Reddy's Laboratories	India	Commercial production	GMP-certified	Approx. 3-5 metric tons annually	Supplies to global markets, including the US and Europe
Zhejiang Hisun Pharmaceuticals	China	Active API manufacturing	GMP standards	Estimated 2-4 metric tons annually	Focuses on Asian markets, expanding global footprint
Mylan (now part of Viatris)	USA	Contract manufacturing	GMP certifications	Estimated 1-3 metric tons annually	Supplies via global contract manufacturing organizations (CMOs)

Distribution and Supply Chain Considerations

• Supply networks mainly involve CDMOs (Contract Development and Manufacturing Organizations) in India, China, and Japan.

• API quality and regulatory status is critical; GMP certification is standard for APIs supplied for global markets.

• Regulatory jurisdictions influence API sourcing; API producers shipping to North America or Europe typically hold certifications aligned with FDA or EMA standards.

• Pricing varies based on production volume, certification status, and buyer-supplier relationships. Estimated costs range from $15 to $30 per gram.

API Sourcing Geographies

• Japan: Home to the original manufacturer, Otsuka. API sourcing here offers reliability and familiarity with regulatory standards but may come at a premium price.

• India: Hosts multiple GMP-certified manufacturers (e.g., Dr. Reddy's). Offers cost-effective options with established export channels.

• China: Increasing capacity for Tolvaptan API, with many manufacturers able to supply at competitive prices; quality varies, so due diligence is necessary.

• Others: Limited suppliers in Europe and the US primarily focus on formulation development rather than bulk API production.

Supply Chain Risks and Market Outlook

• Supply disruption risks include geopolitical issues, manufacturing capacity constraints, and raw material shortages.

• Market growth is driven by the increasing prevalence of ADPKD and SIADH, with regulatory approvals expanding API requirements.

• Future capacity expansion may come from new entrants in India and China responding to rising demand.

Regulatory and Quality Guidelines

• API suppliers must comply with Good Manufacturing Practices (GMP) as enforced by regulatory authorities like the FDA, EMA, and local agencies.

• Certificates of Analysis (CoA), Certificates of Suitability (CEPs), and batch documentation are necessary for validating API quality.

• Many suppliers hold multiple certifications, ensuring acceptance across regulatory jurisdictions.

Summary

Primary bulk API sources for Tolvaptan include established Japanese manufacturers (Otsuka and Kissei), Indian firms (Dr. Reddy’s), and Chinese suppliers (Zhejiang Hisun). Market dynamics favor Indian and Chinese suppliers for cost advantages, provided rigorous quality assessments are performed. The market remains relatively concentrated; limited global competition sustains pricing stability.

---

Key Takeaways

• Otsuka is the original and primary Tolvaptan API supplier, with high-quality, GMP-certified production.
• India and China host numerous GMP-compliant manufacturers capable of supplying bulk API at competitive prices.
• Supply chain risks include geopolitical factors, capacity constraints, and raw material access, affecting stability.
• Regulatory certifications, GMP adherence, and quality documentation are essential for sourcing.
• Market expansion in ADPKD and hyponatremia treatments sustains demand and potential supply chain growth.

---

FAQs

Q1: Which countries dominate the bulk API production for Tolvaptan?
A1: Japan, India, and China are the primary countries producing Tolvaptan APIs, with Japan hosting the original producer, and India and China providing cost-effective options.

Q2: What certifications are necessary for suppliers?
A2: Suppliers should hold GMP certification aligned with FDA, EMA, or other relevant authorities, along with Certificates of Analysis and Certificate of Suitability.

Q3: What are the main supply risks?
A3: Risks include raw material shortages, geopolitical disruptions, manufacturing capacity limitations, and regulatory testing delays.

Q4: How is pricing structured for Tolvaptan API?
A4: Pricing typically ranges from $15 to $30 per gram, influenced by order volume, certification level, and geographic supplier location.

Q5: Are new suppliers entering the market?
A5: Yes, manufacturers in India and China are expanding capacities to meet rising global demand driven by ADPKD and SIADH treatment needs.

---

References

1. Otsuka Pharmaceutical Co. (2022). Product details and manufacturing standards.
2. Kissei Pharmaceutical Co. (2021). Licensing and manufacturing data.
3. Dr. Reddy's Laboratories. (2023). API manufacturing capabilities.
4. Zhejiang Hisun Pharmaceuticals. (2022). Market expansion and quality certification.
5. Mylan (Viatris). (2022). Contract manufacturing and supply chain overview.